Key Finding :
Combination therapy with trifluridine-tipiracil and bevacizumab slows disease progression and enhances survival in patients with refractory metastatic colorectal cancer, according to an international randomised trial in the New England Journal of Medicine .
Background and/or implications :
A trial published in 2015 found that trifluridine-tipiracil (trifluridine slows ...
